Core Viewpoint - The FDA is considering revoking the emergency use authorization of Pfizer's Covid-19 vaccine for healthy children under 5, which could limit vaccination options for this age group [1][4]. Group 1: FDA's Consideration and Impact - The potential revocation could leave many children without available vaccination options against Covid-19, as alternatives from Moderna and Novavax are only authorized for limited populations [2]. - If the FDA proceeds with the revocation, it would reflect ongoing changes in immunization policy under the leadership of HHS Secretary Robert F. Kennedy Jr., who has been critical of vaccines [3][5]. Group 2: Pfizer's Response and Current Status - Pfizer has confirmed that it is in discussions with the FDA regarding the authorization and has requested that it remain in place for the upcoming fall and winter season [4]. - The FDA's deliberations are stated not to be related to the safety and efficacy of the vaccine, which Pfizer claims continues to show a favorable profile [4]. Group 3: Comparison with Other Vaccines - In July, the FDA granted full approval to Moderna's Covid vaccine for children with health conditions, while Novavax's vaccine has never been available for children under 12 [5]. - The CDC has also altered its recommendations regarding Covid vaccines for healthy children and pregnant women, indicating a shift in vaccination guidance [6].